Navigation Links
Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Date:2/6/2013

ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release fourth quarter and full year 2012 financial results on Tuesday, February 26, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 26, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter and full year, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 95427085.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications:  the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, the treatment of infantile spasms in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
2. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
3. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
4. Questcor to Conduct Conference Call to Discuss Reimbursement Process
5. Questcor Comments on Insurance Policy Bulletin
6. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
7. Questcor Pharmaceuticals to Present at Investor Conferences in September
8. Questcor Reports Second Quarter Financial Results
9. Questcor to Report Second Quarter Results on July 24, 2012
10. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de enfermedades infecciosas, presentó ... a los miembros de la Kenya Pharmaceutical Association. ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... ) bioLytical fue invitada por la Clinton Health Access Initiative ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
(Date:12/2/2016)... FRANCISCO , Dec. 2, 2016  PipelineRx, a ... telepharmacy, will be offering demonstrations of its SaaS-based ... Society of Health-System Pharmacists 2016 Midyear Clinical Meeting ... Vegas . With nearly 300 hospital clients ... services and technology designed to dramatically improve pharmacy ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel ... CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. ... brings extensive financial and operational leadership experience to Advanced Inc. He began his career ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... from high school and while 84 percent of parents report speaking with their child ... control, pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 ... to create versatile lower third titles with just a few clicks of the mouse," ... 2 includes 30 lower third animations. Choose from various styles with accented animations, rigid ...
Breaking Medicine News(10 mins):